NEW YORK, NY / ACCESSWIRE / June 26, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Ryder System, Inc. (NYSE:R)
CONTACT JAKUBOWITZ ABOUT R:
https://claimyourloss.com/securities/ryder-system-inc-loss-submission-form/?id=7592&from=1
Class Period : July 23, 2015 - February 13, 2020
Lead Plaintiff Deadline : July 20, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Endo International Plc (NASDAQ:ENDP)
CONTACT JAKUBOWITZ ABOUT ENDP:
https://claimyourloss.com/securities/endo-international-plc-loss-submission-form/?id=7592&from=1
Class Period : August 8, 2017 - June 10, 2020
Lead Plaintiff Deadline : August 18, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Chembio Diagnostics, Inc. (NASDAQ:CEMI)
CONTACT JAKUBOWITZ ABOUT CEMI:
https://claimyourloss.com/securities/chembio-diagnostics-inc-loss-submission-form/?id=7592&from=1
Class Period : March 12, 2020 - June 16, 2020
Lead Plaintiff Deadline : August 17, 2020
According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law